Kolinsky, Kenneth

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 708

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 283

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 216

Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach

Higgins, B., Glenn, K., Walz, A., Tovar, C., Filipovic, Z., Hussain, S., Lee, E., Kolinsky, K., Tannu, S., Adames, V., et al. (2014) · Clinical Cancer Research

Cancer-related Molecular PathwaysMathematical Biology Tumor Growth

Cited by 63